Trinity Biotech (TRIB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Trinity Biotech (TRIB) is Moderate Underperform.

The composite score behind that read is -0.30, weighing +0.07 of bullish evidence against -0.57 bearish.

Trinity Biotech last closed at $6.86, +13.58% on the session.

Against the IVW growth benchmark the position is +12.78% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

19 graded predictions for TRIB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Trinity Biotech in the 93rd percentile on return on equity, where 100 is best.

Trinity Biotech is classified under Health Care / Health Care Equipment & Supplies, with a market capitalisation of $4.91M.

StockMap tracks Trinity Biotech as the 138th largest of the 140 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 122 Neutral, 16 Moderate Underperform and 2 Moderate Outperform.

On that composite Trinity Biotech ranks 137th of 140 in the group, against a group median of -0.03.